We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01215058
First Posted: October 5, 2010
Last Update Posted: October 22, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this study is to assess gastroprotective agent compliance in patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer with NSAID.

Condition
Gastrointestinal Hemorrhage Ulcer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal Bleeding Ulcer or a Symptomatic Ulcer With Non-steroidal Anti-inflammatory Drug (NSAID) in France

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Gastroprotective agent compliance [ Time Frame: At the end of 1 month ]

Secondary Outcome Measures:
  • Clinical characteristics of those ulcers with NSAID [ Time Frame: At the end of 1 month ]

Enrollment: 0
Study Start Date: October 2010
Estimated Study Completion Date: April 2011
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Hospital sample
Criteria

Inclusion Criteria:

  • Patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer confirmed by endoscopy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01215058


Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Jean-Francois Bretagne Service gastro-enterologie et hepatologieCHRU Pontchaillou35033 RENNES cedex France
Study Chair: Gerard Thiefin Service Hepato-Gastroenterologie CHU Reims51092 REIMS cedex France
Principal Investigator: Genevieve BONNELYE KantarHealth - France138, avenue Marx Dormoy92120 Montrouge cedex
  More Information

Responsible Party: Marketing Company Medical Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT01215058     History of Changes
Other Study ID Numbers: NIS-PFR-DUM-2010/2
First Submitted: September 28, 2010
First Posted: October 5, 2010
Last Update Posted: October 22, 2010
Last Verified: October 2010

Keywords provided by AstraZeneca:
Compliance, France
Gastrointestinal bleeding ulcer or symptomatic ulcer with NSAID

Additional relevant MeSH terms:
Ulcer
Hemorrhage
Gastrointestinal Hemorrhage
Pathologic Processes
Gastrointestinal Diseases
Digestive System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents